Ivokana (canagliflozan) is a recently approved drug for the treatment of type two diabetes. Approved in the US in 2013. It is a subtype 2 sodium-glucose transport protein inhibitor, or more commonly referred to as a SGLT2 inhibitor. This medication increases urinary glucose excretion by lowering the reabsorption of filtered glucose. Initial dose is 100mg before the first meal of the day. The dose can be increased to 300mg once daily. It is important to drink plenty of fluids to prevent dehydration as more fluids will be excreted through the urine once starting this medication. Common adverse effects include UTI (in women) and an increase in serum potassium. Others include nausea and orthostatic hypotension.
Invokana (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; May 2014. Invokana (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2014.
Delighted that I found your site, fantastic info. It really gives me an insight on this topic.
ReplyDeleteInvokana attorney